Division of Pulmonary, Allergy and Critical Care Medicine

Home

Address:

Columbia University, College of Physicians & Surgeons
630 West 168th Street

P&S 8, Room 503

New York, NY 10032

Mailing Address:

Columbia University, College of Physicians & Surgeons

630 West 168th Street
Box 91
New York, NY 10032

Phone: 212-305-3584

cap6@columbia.edu

Lung Cancer Links

Charles A. Powell, M.D.

Florence Irving Assistant Professor of Clinical Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

Director, Pulmonary & Critical Care Fellowship

Clinical and Research Interests

Dr. Powell’s primary clinical and research interests are lung cancer and mesothelioma. Specific areas of clinical interest include:
* CT screening for the early detection of lung cancer
* Evaluation of pulmonary nodules
* Diagnostic fiberoptic bronchoscopy

* Endobronchial ultrasound-guided transbronchial needle aspiration
* Staging of lung cancer with PET imaging and bronchoscopy

* Biomarkers of Lung Cancer Diagnosis and Prognosis
* Chemoprevention of lung cancer

Dr. Powell’s research is directed to the to the identification of novel molecular biomarkers that will be useful for the early detection, prevention and treatment of lung carcinoma.

Education and Training

B.A., Economics, University of Pennsylvania, 1985
M.D., University of Chicago Pritzker School of Medicine, 1989
Residency, Columbia Presbyterian Medical Center
Fellowship, Boston University Pulmonary Center

Honors

Phi Beta Kappa, 1985
Summa cum laude, 1985
Florence Irving Scholar, 2002

Powell Lab

Publications

1. Powell CA., and Joyce-Brady M. Acute and Chronic Respiratory Failure. In: Goldstein RH, O’Connell JJ, Karlinsky JB, eds. A Practical Approach to Pulmonary Medicine. Boston: Little, Brown and Company 1997; 296-308.

2. Powell CA, Klares S, O’Connor G, Brody JS. Loss of Heterozygosity in Epithelial Cells Obtained by Bronchial Brushings: Clinical Utility in Lung Cancer. Clinical Cancer Research 1999; 5:2025-34.

3. Powell CA, Caplan CE. Pulmonary Function Tests in Preoperative Pulmonary Evaluation. Clinics in Chest Medicine 2001; 22:703-14.

4. Powell CA, Xu G, Filmus J, Busch S, Brody JS, Rothman PB. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest 2002; 121 (3 Suppl): 6S-7S.

5. Li C, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, and Tycko B. Gene Expression in Wilms Tumors Mimics the Earliest Committed Stage in the Metanephric Mesenchymal-Epithelial Transition. American Journal of Pathology 2002; 160:2181-90.

6. Powell CA, Caracta C, Bueno R, Richards WG, Sugarbaker DJ, Brody JS. Distinct Patterns of Allelic Loss in Lung Adenocarcinoma of Non-Smokers Lung Cancer 2003; 39: 23-29.

7. Powell CA, Spira A, Derte A, DeLisi C, Sugarbaker DJ, Bueno R, Richards W, Brody JS. Gene expression in lung adenocarcinomas of smokers and nonsmokers. American Journal of Respiratory Cell and Molecular Biology 2003; 29: 157-62.

8. Kim H, Xu G, Borczuk A, Busch S, Filmus J, Capurro M, Brody JS, Lange J, D’Armiento JM, Rothman PB, Powell CA. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. American Journal of Respiratory Cell and Molecular Biology 2003; 29: 694-701.

9. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA. Non-small cell lung cancer molecular signatures recapitulate lung developmental pathways. American Journal of Pathology 2003, 163: 1949-1960.

10. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M, CDX2 Immunostaining as a gastrointestinal marker: Expression in lung carcinomas is a potential pitfall, Applied Immunohistochemistry & Molecular Morphology 2004; In Press.

11. Borczuk AC, Shah L, Pearson GDN, Walter KL, Wang L, Austin JHM, Friedman RA, Powell CA.
Molecular signatures in biopsy specimens of lung cancer, American Journal of Respiratory and Critical Care Medicine 2004, 170: 167-174.

12. Shah L, Walter KL, Borczuk AC, Kawut SM,Sonett JR, Gorenstein LA, Ginsburg ME, Steinglass KM, Powell CA. Expression of Syndecan-1 and Epidermal growth factor receptor is associated with survival in non-small cell lung cancer. Cancer 2004; 101: 1632-1638.

13. Foronjy RF, Mercer BA, Maxfield MW, Powell CA, D’Armiento J. Structural emphysema does not correlate with lung compliance: Lessons from the mouse smoking model. Experimental Lung Research 2005; 31:547-562.

14. Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML, Alsberry R, Alexis D, Powell CA. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clinical Cancer Research 2005; 11:3303-8.

15. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA. Lung adenocarcinoma global profiling identifies Type II TGF-ß receptor as a repressor of invasiveness. American Journal of Respiratory and Critical Care Medicine 2005; 172: 729 – 737.

16. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M. CDX2 Immunostaining as a gastrointestinal marker: Expression in lung carcinomas is a potential pitfall. Applied Immunohistochemistry & Molecular Morphology 2005; 13: 55 – 60.

17. Saqi A, Yun SS, Yu GH, Alexis D, Taub RN, Powell CA, Borczuk AC. Utility of CD138 (Syndecan-1) in Distinguishing Carcinomas from Mesotheliomas. Diagnostic Cytopathology 2005; 33:65-70.

18. Mercer BA, Lemaitre V, Powell CA, D’Armiento. The Epithelial Cell in Lung Health and Emphysema Pathogenesis. Current Respiratory Medicine Reviews 2006; 2:101-142.

19. Shao G, Berenguer J, Borczuk AC, Powell CA, Hei TK, Zhao Y. Epigenetic inactivation of Betaig-h3 in human cancer cells. Cancer Research 2006; 66:4566-4573.

20. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GDN, Shiau MC, Raftopoulos H. Clinical predictors of metastatic disease to the brain from non-small cell carcinoma of the lung: Size of the primary tumor, cell type, and lymph node metastases. Radiology 2007; 242: 882 – 888.

21. Borczuk AC, Cappellini GCA, Kim HK, Hesdorffer M, Taub RN, Powell CA. Molecular Profiling of Malignant Peritoneal Mesothelioma Identifies the Ubiquitin- Proteasome Pathway as a Therapeutic Target in Poor Prognosis Tumors, Oncogene 2007; 26:610-617.

22. Borczuk AC, Powell CA. Expression Profiling and Lung Cancer Development. Proceedings of the American Thoracic Society 2007; 4:127-132.

23. Bruce B, Khanna G, Ren L, Landberg G, Jurstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM. Expression of the Cytoskeleton Linker Protein Ezrin in Human Cancers. Clinical Experimental Metastasis 2007; 24: 69-78.

24. Vachani A, Nebozhyn M, Singhal S, Alila L, Wakeam E, Muschel R, Powell CA, Gaffney P, Singh B, Brose MS, Litzky LA, Kucharczuk J, Kaiser LR, Marron JS, Showe MK, Albelda SM, Showe LC. A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma. Clinical Cancer Research 2007; 10: 2905 – 2915.

25. Dubey S, Powell CA. Update in Lung Cancer 2006. American Journal of Respiratory and Critical Care Medicine 2007; 175: 868-874.

26. Borczuk AC, Papankikolaou N, Toonkel RL, Sole M, Gorenstein LA, Ginsburg ME, Sonett JS, Friedman RA, Powell CA. Lung Adenocarcinoma Invasion in TGFβRII Deficient Cells is Mediated by CCL5/RANTES. Oncogene 2007:In Press.